<DOC>
	<DOCNO>NCT01013753</DOCNO>
	<brief_summary>The primary objective study determine efficacy safety 4 dos BI 1744 CL inhalation solution deliver RespimatÂ® inhaler daily four week patient asthma comparison placebo .</brief_summary>
	<brief_title>A Study Safety Efficacy 4 Doses BI 1744 CL Delivered Via Respimat Patients With Asthma .</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Inclusion criterion : 1 . All patient must sign informed consent consistent International Conference HarmonisationGood Clinical Practice ( ICHGCP ) guideline prior participation trial , i.e . prior study procedure include medication washout restriction . A separate informed consent require pharmacogenomic sampling . 2 . Male female patient , age 18 70 year age , diurnally active 3 . A history asthma diagnose physician least 3 month prior Visit 1 GINA treatment step 3 4 . The diagnosis asthma must make age 40 . 4 . Prebronchodilator FEV1 60 % predict 90 % predict Visit 1 . 5 . Increase FEV1 great equal 12 % 200 ml 15 minute 400mcg salbutamol ( albuterol ) Visit 1 . 6 . Patient must take inhaled corticosteroid ( ICS ) least 12 week prior screen , must receive stable dose least 6 week prior screen either : medium high dose ICS low high dose ICS combination Long act beta agonist ( LABA ) . 7 . All patient must symptomatic . Exclusion criterion : 1 . Patients significant disease asthma ; significant disease define disease , opinion investigator , may ( ) put patient risk participation study , ( ii ) influence result study , ( iii ) cause concern regard patient 's ability participate study 2 . Patients hospitalise asthma exacerbation within 3 month admission intensive care unit asthma within 3 year Visit 1 3 . Patients exclude : aspartate aminotransferase ( AST ) &gt; 80 IU/L , alanine aminotransferase ( ALT ) &gt; 80 IU/L , bilirubin &gt; 1.5 X upper limit normal ( ULN ) creatinine &gt; 1.5 X ULN clinically relevant abnormal baseline haematology , blood chemistry , urinalysis 4 . Patients follow condition : diagnosis thyrotoxicosis diagnosis paroxysmal tachycardia ( &gt; 100 beat per minute ) mark baseline prolongation QT/QTc interval Visit 1 ( e.g. , repeat demonstration QTc interval &gt; 450 m ) recommend ICH E14 history additional risk factor Torsade de Pointes ( TdP ) ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) recommend ICH E14 . 5 . Patients follow condition : history myocardial infarction within 1 year screen visit ( Visit 1 ) diagnosis clinically relevant cardiac arrhythmia history cor pulmonale know active tuberculosis malignancy patient undergone resection , radiation therapy chemotherapy within last five year ( patient treat basal cell carcinoma allow ) history lifethreatening pulmonary obstruction history chronic obstructive pulmonary disease history cystic fibrosis clinically evident bronchiectasis history significant alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>